CoChat
Sign Up
Cited by 10

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Novel Strategies for Managing Dyslipidemia: Treatment beyond Statins

Ling, Hua, Burns, Tammy L., Hilleman, Daniel E.·2012·Postgraduate Medicine
DOI 10.3810/pgm.2012.11.2612
Open this paper in CoChat — free account

Abstract

Purpose This article reviews the current status of lipid-lowering drugs and their impact on cardiovascular morbidity and mortality. Because there is compelling evidence to suggest that substantial residual risk persists despite the use of current lipid-lowering treatments, novel strategies for managing dyslipidemia are discussed. Summary Statins remain the drugs of choice for the treatment of dyslipidemia in patients with coronary heart disease or substantial risk factors for coronary heart disease. The evidence supporting the use of non-statin monotherapy for reductions in cardiovascular morbidity and mortality is examined. Furthermore, the evidence supporting the use of combinations of lipid-lowering drugs, primarily a statin plus another agent, for reductions in cardiovascular morbidity and mortality is discussed. Available clinical data for novel dyslipidemia drugs that can potentially expand on the current known benefits of statin therapy are reviewed. The cholesteryl ester transfer protein inhibitors, which predominantly increase high-density lipoprotein cholesterol levels and can also substantially lower low-density lipoprotein cholesterol levels, have the most robust clinical trial data, including some phase 3 study results. The proprotein convertase subtilisin/kexin type 9 inhibitors, which predominantly impact low-density lipoprotein cholesterol, are also being tested in phase 3 studies, but their widespread application may be limited by their need to be administere…

Overview

Integrity signals

Registry

Crossref · 10.3810/pgm.2012.11.2612

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 62

  1. Omran AR, 1971, Milbank Mem Fund Q., 49, 509, 10.2307/3349375 · DOI
  2. Mackenbach JP, 1994, J Epidemiol Comm Health., 48, 329, 10.1136/jech.48.4.329-a · DOI
  3. Moriyamal M, 1964, Vital Health Stat 1., 127, 1
  4. Dawber TR, 1957, Am J Public Health Nations Health., 47, 4, 10.2105/AJPH.47.4_Pt_2.4 · DOI
  5. Dawber TR, 1951, Am J Public Health Nations Health., 41, 279, 10.2105/AJPH.41.3.279 · DOI · Paper page
  6. Dawber TR, 1959, Am J Public Health Nations Health., 49, 1349, 10.2105/AJPH.49.10.1349 · DOI
  7. Dawber TR, 1961, Mod Concepts Cardiovasc Dis., 30, 671
  8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, JAMA., 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  9. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate, 1978, Br Heart J., 40, 1069, 10.1136/hrt.40.10.1069 · DOI
  10. 1975, JAMA., 231, 360, 10.1001/jama.1975.03240160024021 · DOI
  11. The Lipid Research Clinics Coronary Primary Prevention Trial results, 1984, JAMA., 251, 351, 10.1001/jama.1984.03340270029025 · DOI · Paper page
  12. Frick M, 1987, JAMA., 317, 1237
  13. The treatment of cerebrovascular disease with Clofibrate, 1973, Stroke., 4, 684, 10.1161/01.STR.4.4.684 · DOI
  14. 2000, Circulation., 102, 21, 10.1161/01.CIR.102.1.21 · DOI · Paper page
  15. 10.1136/bmj.325.7373.1139 · DOI · Paper page
  16. Rubins HB, 1999, N Engl J Med., 341, 410, 10.1056/NEJM199908053410604 · DOI · Paper page
  17. 1994, Lancet., 344, 1383
  18. 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  19. 10.1016/S0140-6736(03)13636-7 · DOI · Paper page
  20. Ridker PM, 2008, N Engl J Med., 359, 2195, 10.1056/NEJMoa0807646 · DOI · Paper page
  21. 10.1056/NEJMoa040583 · DOI · Paper page
  22. de Lemos JA, 2004, JAMA., 292, 1307, 10.1001/jama.292.11.1307 · DOI · Paper page
  23. 10.1001/jama.294.19.2437 · DOI · Paper page
  24. Wanner C, 2005, N Engl J Med., 353, 238, 10.1056/NEJMoa043545 · DOI · Paper page
  25. Holdaas H, 2003, Lancet., 361, 2024, 10.1016/S0140-6736(03)13638-0 · DOI · Paper page
  26. 10.1517/14656560903376186 · DOI
  27. 10.1056/NEJMoa050461 · DOI · Paper page
  28. Miller M, 2008, J Am Coll Cardiol., 51, 724, 10.1016/j.jacc.2007.10.038 · DOI · Paper page
  29. Rossebø AB, 2008, N Engl J Med., 359, 1343, 10.1056/NEJMoa0804602 · DOI · Paper page
  30. 10.1056/NEJMoa1107579 · DOI · Paper page
  31. Tall AR, 1993, J Lipid Res., 34, 1255, 10.1016/S0022-2275(20)36957-1 · DOI · Paper page
  32. Gurfinkel R, 2011, Cardiovasc Ther., 29, 327, 10.1111/j.1755-5922.2010.00142.x · DOI
  33. 10.1056/NEJMoa0706628 · DOI · Paper page
  34. Forrest MJ, 2008, Br J Pharmacol., 154, 1465, 10.1038/bjp.2008.229 · DOI
  35. 10.1016/S0140-6736(11)61383-4 · DOI
  36. Lüscher TF, 2012, Eur Heart J., 33, 857, 10.1093/eurheartj/ehs019 · DOI
  37. Schwartz GG, 2009, Am Heart J., 158, 896, 10.1016/j.ahj.2009.09.017 · DOI
  38. 2012, Roche provides update on phase III study of dalcetrapib [media release]
  39. 10.1016/j.ahj.2008.09.022 · DOI
  40. Lambert G, 2009, Atherosclerosis., 203, 1, 10.1016/j.atherosclerosis.2008.06.010 · DOI
  41. Cohen JC, 2006, N Engl J Med., 354, 1264, 10.1056/NEJMoa054013 · DOI · Paper page
  42. Awan Z, 2012, Clin Chem., 58, 183, 10.1373/clinchem.2011.172932 · DOI
  43. Abifadel M, 2010, Expert Opin Ther Pat., 20, 1547, 10.1517/13543776.2010.518615 · DOI
  44. Dias C, 2012, J Am Coll Cardiol., 59, E1379, 10.1016/S0735-1097(12)61380-1 · DOI
  45. 10.1016/j.jacc.2012.03.007 · DOI
  46. 10.1016/S0140-6736(12)60771-5 · DOI
  47. Agnello V, 1999, Proc Natl Acad Sci USA., 96, 12766, 10.1073/pnas.96.22.12766 · DOI
  48. 10.1016/j.phrs.2007.03.002 · DOI
  49. 10.1016/S0140-6736(09)60870-9 · DOI
  50. Ito MK, 2007, Ann Pharmacother., 41, 1669, 10.1345/aph.1K065 · DOI
  51. 10.1093/eurheartj/ehs084 · DOI
  52. KYNAMRO (mipomersen sodium)
  53. 10.1016/S0140-6736(10)60284-X · DOI
  54. Hussain MM, 2003, J Lipid Res., 44, 22, 10.1194/jlr.R200014-JLR200 · DOI · Paper page
  55. 10.1186/1750-1172-3-19 · DOI
  56. 2011, FDA grants orphan drug designation to aegerion pharmaceuticals' drug candidate, lomitapide, for treatment of familial chylomicronemia [press release]
  57. 2012, Aegerion pharmaceuticals announces lomitapide 78-week phase III clinical data consistent with earlier results [press release]
  58. Cuchel M, 2010, Atherosclerosis Supplements., 11, 14, 10.1016/S1567-5688(10)70065-9 · DOI
  59. Shin JJ, 2003, J Biol Chem., 278, 34114, 10.1074/jbc.M305417200 · DOI
  60. Baxter JD, 2009, Nat Rev Drug Discov., 8, 308, 10.1038/nrd2830 · DOI · Paper page
  61. Grover GJ, 2003, Proc Natl Acad Sci USA., 100, 10067, 10.1073/pnas.1633737100 · DOI
  62. Ladenson PW, 2010, N Engl J Med., 362, 906, 10.1056/NEJMoa0905633 · DOI

Cited by

Sorted by citations

Metadata

Authors
Ling, H., Burns, T. L., & Hilleman, D. E.
Venue
Postgraduate Medicine
Publisher
Informa UK Limited
Published
2012-11
Volume
124
Issue
6
Pages
43-54
ISSN
  • 0032-5481
  • 1941-9260
DOI
10.3810/pgm.2012.11.2612
Cited by
10
References
11
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review